Regulation FD Presentation (Form 8-K)

September 12, 2025

Dear Fellow Shareholders,

I am writing to provide a straightforward update on what Health Discovery Corporation ("HDC", or the "Company") has been working on and how we are positioning the Company moving forward.

In the near-term, our top priorities are protecting the value of our intellectual property ("IP") and restoring our reporting with the Securities Exchange Commission ("SEC") so our shares can again trade on a recognized U.S. over-the-counter (OTC) marketplace.

Intellectual Property Protection

Over the past year, we believe that we have identified potential infringement of certain HDC intellectual property, including U.S. Patent No. 10,402,685 (the "'685 Patent"). While this patent expired in June of 2025, an infringing party may be liable for damages for a six-year lookback period. Guided by outside counsel, we are pursuing protection and enforcement to the fullest, which may include formal notices, licensing discussions, and, if warranted, litigation. To avoid prejudicing any potential lawsuit, we are keeping the identity of the counterparty and our legal strategy confidential at this time; however, we are preserving evidence, continuing technical claim analyses, and evaluating remedies and venues consistent with counsel's advice.

While we believe our claims have merit, we cannot guarantee success in any enforcement action. Outcomes of controversies of this nature are inherently uncertain and depend on a variety of factors, including facts, law, venue, timing, counterclaims and resources.

Financials, Audit & Reporting Readiness

With the objective of becoming current in our reporting with the SEC, we have engaged a bookkeeping provider and an independent registered public accounting firm to help bring our financials current and align our reporting with requirements under federal securities laws.

Once this effort is completed, we plan to once again list our shares for trading on a recognized U.S. OTC marketplace. This would entail identifying an exchange for which we are eligible (as the historic OTC Bulletin Board on which we previously traded was discontinued), submitting an application and undergoing a review and approval process. We cannot guarantee that HDC will be listed on an OTC marketplace in the future.

Leadership & Governance

Our Board of Directors believes that it is in the best interest of HDC and our shareholders to maintain continuity in leadership as we strive to accomplish the objectives discussed above. Accordingly, the Board has approved an extension of the Chief Executive Officer's employment agreement, subject to definitive documentation. The employment agreement will not guarantee continued service and will include, among other terms, customary termination provisions.

Key Risk Factors

Below is a discussion of material risk factors, which is limited to the matters discussed in this letter. This should not be construed as an exhaustive list of risks that may affect our business. The following issues, uncertainty and risks, among others, should be taken into account in evaluating our business and outlook.